What's in Eldon Loh, MD's pipeline?

Eldon Loh, MD has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eldon Loh, MD's portfolio?

Top competitors by shared drug class: Centre for Addiction and Mental Health, NEMA Research, Inc., University of Calgary.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eldon-loh-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Eldon Loh, MD — Portfolio Competitive Intelligence Brief

Eldon Loh, MD pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Nabilone Capsules	Nabilone Capsules	phase 3	Synthetic cannabinoid	CB1 receptor, CB2 receptor	Oncology, Gastroenterology

Therapeutic area mix

Oncology, Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Centre for Addiction and Mental Health · 1 shared drug class
NEMA Research, Inc. · 1 shared drug class
University of Calgary · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eldon Loh, MD:

Cite this brief

Drug Landscape (2026). Eldon Loh, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eldon-loh-md. Accessed 2026-05-14.